Evidence map›Paper›PMID 25981401›Full record

ArticleWorld journal of urology2015

Effects of phosphodiesterase-5 inhibitor on ischemic kidney injury during nephron sparing surgery: quantitative assessment by NGAL and KIM-1.

Yousef Lahoud, Osamah Hussein, Amjad Shalabi, Omri Nativ, Hoda Awad, Mogher Khamaisi, Ibrahim Matar, Ofer Nativ, Zaid Abassi

Abstract readControlled Clinical Trial
PubMed Publisher
In one paragraph

Article in World journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Urinary NephroCheckBMC nephrology · 2025
    Observational
  2. Article
  3. Article
  4. Review
  5. Acute Renal Failure Following Near-Drowning.Kidney international reports · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yousef LahoudDepartment of Internal Medicine A, Faculty of Medicine, Ziv Hospital, Bar-Ilan University, Safed, Israel.
Osamah HusseinDepartment of Internal Medicine A, Faculty of Medicine, Ziv Hospital, Bar-Ilan University, Safed, Israel.
Amjad ShalabiDepartment of General Surgery, Rambam Health Campus, Haifa, Israel.
Omri NativDepartment of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion, IIT, P.O. Box 9649, 31096, Haifa, Israel.
Hoda AwadDepartment of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion, IIT, P.O. Box 9649, 31096, Haifa, Israel.
Mogher KhamaisiDepartment of Internal Medicine C, Institute of Endocrinology, Rambam Health Campus, Haifa, Israel.
Ibrahim MatarDepartment of Surgery, Bnai Zion Hospital, 31096, Haifa, Israel.
Ofer NativDepartment of Urology, Bnai Zion Hospital, 47 Golomb St., 31096, Haifa, Israel. ofer.nativ@b-zion.org.il.
Zaid AbassiResearch Unit, Rambam Health Campus, Haifa, Israel. abassi@tx.technion.ac.il.
Bar-Ilan University · ILBnai Zion Medical Center · ILRambam Health Care Campus · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeInterruption of renal blood flow is often necessary during nephron sparing surgery (NSS) and can induce renal injury. This study examines whether tadalafil, a phosphodiesterase-5 (PDE-5) inhibitor and well-known vasodilator, exerts nephroprotective effects in patients undergoing NSS.

methodsThis non-randomized study included 49 patients with enhancing solid renal mass. All patients were subjected to open NSS during which clamping the renal artery was performed. Twenty-two patients were pretreated with tadalafil 1 day prior NSS and 2 days following surgery. The other 27 patients underwent the same surgical procedure but did not receive tadalafil (controls). Urine samples were collected before surgery and following renal pedicle clamp removal. Urine levels of NGAL and KIM-1, two novel biomarkers for acute kidney injury (AKI), were determined.

resultsClamping the renal artery induced kidney dysfunction as reflected by increases in urinary NGAL and KIM-1 in all participants. These increases in urinary NGAL and KIM-1 excretion were evident 1 h after renal ischemia and lasted for 72 and 24 h, respectively. Pretreatment with tadalafil reduced the absolute urinary excretion of KIM-1, but not of NGAL. Although the incidence of AKI was comparable between tadalafil-treated and untreated NSS subjects, the elevation in serum creatinine (SCr) was significantly attenuated in tadalafil-treated group as compared with NSS controls.

conclusionsTadalafil exerts nephroprotective effects in AKI following NSS, as was evident by reduced urinary excretion of KIM-1 and attenuation of SCr elevation. Carefully controlled large clinical studies are needed before defining the role of PDE-5 inhibition therapy in these patients.

Indexed as

Acute Kidney InjuryAcute-Phase ProteinsAdultAgedAged, 80 and overBiomarkersCarcinomaCreatinineFemaleHepatitis A Virus Cellular Receptor 1HumansIschemiaKidney NeoplasmsLipocalin-2LipocalinsMaleAcute-Phase ProteinsBiomarkersCreatinineHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1LCN2 protein, humanLipocalin-2LipocalinsMembrane GlycoproteinsPhosphodiesterase 5 InhibitorsProto-Oncogene ProteinsReceptors, VirusTadalafilAcute kidney injuryKIM-1Nephron sparing surgeryNGALTadalafil

Identifiers

PMID25981401
OpenAlexW1541933553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.